Ability Today to your inbox.
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.
Our Awards and Partners
CAT-4001 is being developed by Catabasis as a potential treatment for neurodegenerative diseases, such as FA and amyotrophic lateral sclerosis (ALS). CAT-4001 is a small molecule that activates Nrf2 and inhibits NF-kB, two pathways that have been ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.